Market Place
Sourcing Support
All News #Library
Regeneron`s Biologics Lynozyfic Receive Approval in US
02 Jul 2025 //
FDA
Regeneron`s Ordspono Receives Approval in Europe
19 Nov 2024 //
EMA
Regeneron`s Biologic Inmazeb Receives Suppl Approval in US
24 Oct 2024 //
FDA
Regeneron`s Biologic Eylea HD (Aflibercept) Receives Suppl Approval in US
10 Oct 2024 //
FDA
Regeneron Pharma`s Biologic Eylea Receives Suppl Approval in US
10 Oct 2024 //
FDA
Regeneron`s Dupixent (dupilumab) Receives Suppl Approval in the U.S.
12 Apr 2024 //
FDA
Regeneron`s Biologic Praluent (alirocumab) Receives Approval in the U.S.
08 Mar 2024 //
FDA
Regeneron`s Biologic Dupixent (dupilumab) Receives Approval in the U.S.
25 Jan 2024 //
FDA
Regeneron`s Biologic Dupixent (dupilumab) Receives Approval in the U.S.
12 Jan 2024 //
FDA
Regeneron`s Biologic Eylea (aflibercept) Receives Approval in the U.S.
14 Dec 2023 //
FDA
Regeneron`s Biologic Eylea (Aflibercept) Receives Approval in the U.S.
18 Aug 2023 //
FDA
Regeneron`s Biologic Veopoz (pozelimab) Receives Approval in the U.S.
18 Aug 2023 //
FDA
Regeneron`s Biologic Dupixent® (dupilumab) Receives Approval in the U.S.
14 Jul 2023 //
FDA
Regeneron`s Biologic Eylea ( Aflibercept) Receives Approval in the U.S.
08 Feb 2023 //
FDA
Regeneron`s Libtayo Receives Approval in Europe
08 Dec 2022 //
EMA
Regeneron`s Biologic Libtayo (Cemiplimab) Receives Approval in the U.S.
08 Nov 2022 //
FDA
Regeneron`s Biologic Dupixent (Dupilumab) Receives Approval in the U.S.
17 Oct 2022 //
FDA
Regeneron`s Biologic Dupixent (Dupilumab) Receives Approval in the U.S.
28 Sep 2022 //
FDA
Regeneron`s Biologic Eylea (Aflibercept) Receives Approval in the U.S.
06 Sep 2022 //
FDA
Regeneron`s Biologic Dupixent (Dupilumab) Receives Approval in the U.S.
07 Jun 2022 //
FDA
Regeneron`s Biologic Dupixent (Dupilumab) Receives Approval in the U.S.
22 Dec 2021 //
FDA
Regeneron`s Biological Dupixent Receives Supplemental Approval in the US
23 Oct 2021 //
FDA
Regeneron`s Biological Dupilumab Receives Supplemental Approval in the US
01 Oct 2021 //
FDA
Regeneron Pharma`s Biological Dupilumab Receives Supplemental Approval In US
01 Oct 2021 //
FDA
Regeneron`s Evkeeza (evinacumab) Receives Approval In Europe
17 Jun 2021 //
EMA
Regeneron`s Biological Dupilumab Receives Supplemental Approval In US
17 Jun 2021 //
FDA
Regeneron`s Arcalyst (rilonacept)Receives Supplemental Approval in US
24 Mar 2021 //
FDA
Regeneron`s Biological Rilonacept Receives Approval In US
19 Mar 2021 //
FDA
Regeneron Libtayo® (cemiplimab-rwlc) Receives Supplemental Approval in US
24 Feb 2021 //
FDA
Regeneron Evkeeza (evinacumab-dgnb) Receives Supplemental Approval in US
17 Feb 2021 //
FDA
Regeneron Arcalyst (Rilonacept) Receives Supplemental Approval in US
22 Dec 2020 //
FDA
Regeneron Pharmaceuticals`s Dupilumab Receives Supplemental Approval in US
26 Jun 2020 //
FDA
Regeneron Pharma`s Eylea (Aflibercept) Receives Supplimental Approval in US
15 May 2019 //
FDA
Regeneron`s Biological Dupilumab Receives Approval in US
24 Oct 2018 //
FDA
Regeneron`s Biological Cemiplimab-Rwlc Receives Supplemental Approval in US
01 Oct 2018 //
FDA
Regeneron Pharmaceuticals`s Generic Aflibercept Receives Approval in US
16 Aug 2018 //
FDA
Regeneron’s Dupilumab Receives Supplemental Approval In US
19 Jan 2018 //
FDA
Regeneron’s Dupixent (Dupilumab ) Receives Supplemental Approval In US
12 Jan 2018 //
FDA
Sanofi Aventis Praluent (Alirocumab) Receives Supplemental Approval In US
21 Apr 2017 //
FDA
Regeneron Pharmaceuticals Dupilumab Receives Supplemental Approval In US
28 Mar 2017 //
FDA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.